Incretin mimetics for type 2 diabetes

References

Citations

1. Exenatide (Byetta) for type 2 diabetes. (2005). Medical Letter on Drugs and Therapeutics, 47(1210): 45–46.

2. Buse JB, et al. (2004). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 27(11): 2628–2635.

3. Kendall DM, et al. (2005). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 28(5): 1083–1091.

4. DeFronzo RA, et al. (2005). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28(5): 1092–1100.

Author:	Merrill Hayden	Last Updated: July 11, 2006
Medical Review:	Caroline S. Rhoads, MD - Internal Medicine Matthew I. Kim, MD - Endocrinology & Metabolism
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.